Drug Profile
TAK 653
Alternative Names: NBI 1065845; NBI-845; TAK 653Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Takeda
- Developer Neurocrine Biosciences; Takeda
- Class Antidepressants; Small molecules
- Mechanism of Action AMPA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Major depressive disorder
- No development reported Depressive disorders
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for phase-I development in Depressive disorders(In volunteers) in Netherlands (PO, Tablet)
- 05 Jan 2022 Phase-II clinical trials in Major depressive disorders (Adjunctive treatment, Treatment-resistant) in USA (PO) as of January 2022 (NCT05203341)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Depressive disorders(In volunteers) in United Kingdom (PO, Tablet)